Cornigerin, a new sesqui-lignan from the hepatoprotective fractions of Cynara cornigera L
Graphical abstract
Introduction
The liver is one of the largest organs in the human body and the main site for intense metabolism and detoxification [1]. Although liver diseases are worldwide problem, it is much more exaggerated in Egypt [2] and in spite of the great advances in modern medicine, no effective medicines are available that could stimulate liver function after damage or help regeneration [3]. Progressive fibrosis occurs after chronic liver injury of any etiology and removing the causative agent is the only effective therapy to stop or even reverse liver fibrosis [4], [5]. Up till now there are no FDA-approved treatments for alcoholic liver disease [6].
Non-alcoholic fatty liver disease (NAFLD) develops when fat builds up within the liver and the mostly affected people are overweight or obese. If the progression of the condition is severe enough, it can lead to liver failure. It is well established that NAFLD is the most common liver disease worldwide with a prevalence rate of 46% in the general population and even a higher rate of 74% among diabetics [7], [8]. NAFLD is strongly associated with insulin resistance and a large portion of NAFLD patients have postprandial hyperinsulinaemia and abnormal glucose tolerance. Recently several studies had proved that NAFLD is an independent strong risk factor for pre-diabetes [9]. A new US study found that nearly one third of children with NAFLD also have prediabetes or type 2 diabetes [10]. Recent studies have shown that silymarin and silibinin appears to be effective in reducing steatosis and insulin resistance [11], [12], [13].
This fact puts a challenge for scientists to explore the potential of hepatoprotective activity of plants based on traditional use where a large number of medicinal preparations are recommended for the treatment of liver disorders [14]. Members of the family Asteraceae especially the tribe Cynareae are known for their efficacy in relieving some liver disorders. In particular Silybum marianum [15], [16], [17], [18], [19], [20] and Cynara scolymus [21], [22], [23] are well known active hepatoprotective agents. Silymarin, obtained from Silybum marianum is a widely used plant derived hepatoprotective agent. Cynareae tribe is represented in Egypt by many genera such as Silybum, Cynara, Centaurea, Carduus, Onopordon and others [24], [25]. Therefore, in an attempt to confront the growing problem of liver diseases in Egypt and worldwide, some plants belonging to the tribe Cynareae growing in Egypt were evaluated for their hepatoprotective activities [26]. Cynara cornigera was found to be active and was selected to carry out a biologically guided fractionation and phytochemical examination of the active fractions.
In the present study, investigation of the hepatoprotective activity of different fractions prepared from the aerial parts of C. cornigera was carried. This was followed by phytochemical investigation of the active fractions which resulted in the isolation of the new sesqui-lignan, 7,8-trans-7′, 8′ -trans- 7″, 8″-cis- 8, 8′- trans-4, 4″, 9, 9″ - tetrahydroxy-3,3′,3″-trimethoxy-4′,8″-5′,7″-dioxy-7,9′-epoxy-lignan-7′-ol (cornigerin). This is the first report of its isolation from nature.
Section snippets
General experimental procedures
Melting points were determined using Gallenkamp, Sanyo, United Kingdom. UV spectra were measured using Pye Unicam SP8-100 UV/VIS spectrophotometer. High Resolution Electrospray Ionization Mass spectrometry (HREIMS) was recorded on Bruker BioApex mass spectrometer. Electron Impact Mass spectroscopy (EI-MS) analysis of compound 1 was performed using MM 7070 E spectrometer. Nuclear magnetic resonance analyses (1H NMR, 13C NMR, DEPT, COSY, HMQC and HMBC) were obtained on a Varian AS 400 MHz
Results and discussion
The UV spectrum of compound 1 in MeOH showed a λmax at 280 nm. The bathochromic shift (14 nm) that occurred upon the addition of dil. NaOH and its colour with FeCl3 indicated the phenolic nature of the compound. The HRESIMS (positive ion mode) showed an [M + Na]+ peak at m/z 593.2012 (calc. 593.1998) and [2 M + Na]+ at m/z 1163.4105 (calc. 1163.4105) suggesting a molecular formula of C30H34O11. The EI-MS showed peaks at m/z 555 (17%) [M-CH3]− and m/z 539 (15%) [M-OCH3]−, confirming the molecular
Conclusion
A new sesqui-lignan along with eight known compounds was isolated from the hepatoprotective fractions of the ethanol extract of Cynara cornigera. The hepatoprotective activity of the isolates is currently underway.
Acknowledgments
The authors thank the Egyptian Government for the partial funding and Dr. Baharthi Avula for HRMS.
References (35)
Possible mechanism of hepatoprotective activity of Azadirachta indica leaf extract: part II
J. Ethnopharmacol.
(2003)- et al.
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy
Gastroenterology
(2011) - et al.
Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis
Dig. Liver Dis.
(2012) - et al.
Milk thistle (Silybum marianum) for the therapy of liver disease
Am. J. Gastroenterol.
(1998) - et al.
Silibinin protects mice from T cell-dependent liver injury
J. Hepatol.
(2003) Antioxidative and protective properties of extract from leaves of the Artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes
Toxicol. Appl. Pharmacol.
(1997)- et al.
A new dilignan from Cynara cardunculus
Fitoterapia
(2003) - et al.
Four new sesqui-lignans isolated from Acanthopanax senticosus and their diacylglycerol acyltransferase (DGAT) inhibitory activity
Fitoterapia
(2016) Caffeoylquinic acids from flowers of Arnica montana and Arnica chamissonis
Phytochemistry
(1992)Herbal preparations as a source of hepatoprotective agents
Drug News Perspect.
(2012)
Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors
Hepatology
Hepatic stellate cells as a target for the treatment of liver fibrosis
Semin. Liver Dis.
Liver fibrosis
J. Clin. Invest.
Treatment of alcoholic liver disease
Ther. Adv. Gastroenterol.
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)
Diabetes Care
Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up
Liver Int.
Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease
JAMA Pediatr.
Cited by (5)
Ethnopharmacology, phytochemistry and pharmacology of potent antibacterial medicinal plants from Africa
2023, Advances in Botanical ResearchThe Effect of Cynara cornigera L. in HepG2 Hepatocellular Carcinoma Cells
2023, Records of Natural ProductsChemical composition and functional properties of Cynara cornigera lindley shoot system extract
2022, Journal of Food Processing and PreservationIranian crack induces hepatic injury through mitogen-activated protein kinase pathway in the liver of Wistar rat
2018, Iranian Journal of Basic Medical SciencesChemical constituents from roots of Viburnum setigerum
2018, Zhongguo Zhongyao Zazhi